Balrampur Chini Mills is on track to launch commercial production at its 80,000-tonne-per-annum polylactic acid facility in the final quarter of financial year 2026-27. Supported by an 88.9% increase in net profit for the September quarter, the firm also declared an interim dividend of ₹4 per share for FY27. Furthermore, Elara Capital upgraded its recommendation to Buy with an ₹874 price target, viewing the upcoming ₹3,080 crore plant and improved sugar realisations as pivotal future growth drivers.
Key points
The new 80,000-tonne-per-annum polylactic acid facility is expected to generate approxima…: The new 80,000-tonne-per-annum polylactic acid facility is expected to generate approximately ₹2,000 crore in annual revenue at full operational capacity.
The company's project qualifies for policy incentives under the Bio Plastic Industrial Po…: The company's project qualifies for policy incentives under the Bio Plastic Industrial Policy introduced by the Uttar Pradesh government.
Regulatory headwinds persist across the sector after India banned the use of sugar for et…: Regulatory headwinds persist across the sector after India banned the use of sugar for ethanol production during the 2026-27 supply year.
Sources checked by our analysis pipeline: 1
Balrampur Chini Mills Ltd is likely to remain in focus as the company expects its ₹3,080 crore polylactic acid (PLA) plant in Uttar Pradesh to commence commercial operations in the fourth quarter of the 2026-27 financial year. The 80,000-tonne-per-annum facility is expected to strengthen the company's presence in the bioplastics sector and emerge as a significant revenue and earnings growth driver over the coming years.
The stock has delivered strong returns to investors, rising over 50% in one year. It has gained 4% in the past three months and 26% over six months. The company's upcoming PLA facility, September-quarter earnings, interim dividend announcement and a recent upgrade by Elara Capital have brought the stock into focus.
Balrampur Chini expects its 80,000-tonne-per-annum PLA plant in Uttar Pradesh to begin commercial operations in Q4FY27. The company is investing around ₹3,080 crore in the project, which is expected to expand its presence in the bioplastics business.
Chairman and Managing Director Vivek Saraogi said in the company's latest investor presentation that construction was progressing at full pace and the project remained largely on track…
Market participants are closely watching trading activity as the company sees an unexpected and rapid upward movement in its valuation. Investors are seeking clarity regarding the sudden momentum during today's session. The aggressive price action is creating notable attention across the broader market.
Benchmark indices reopened following the Diwali-Balipratipada closure after hitting their highest levels since February 2026 earlier in the week. Investors are shifting attention to fresh quarterly earnings and significant industrial contract wins. While brokerage support boosted defence electronics, major manufacturing firms showed severe bottom-line pressure despite strong revenue growth.
Shares of Hims & Hers Health are experiencing a downward trend today. Specific details and underlying reasons for the decline have not yet been provided.